CLN1 (PPT1) — Palmitoyl-Protein Thioesterase 1

CLN1 (PPT1) — Palmitoyl-Protein Thioesterase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CLN1 (PPT1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CLN1</strong></td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Palmitoyl-Protein Thioesterase 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1p34.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/1204" target="_blank">1204</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132128" target="_blank">ENSG00000132128</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/256000" target="_blank">256000</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/O00624" target="_blank">O00624</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Infantile Neuronal Ceroid Lipofuscinosis (INCL)](/diseases/infantile-ceroid-lipofuscinosis)</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal Recessive</td>
</tr>
<tr>
<td class="label">Enzyme Class</td>
<td>Thioesterase</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

CLN1 (PPT1)

Overview

CLN1 (PPT1) — Palmitoyl-Protein Thioesterase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CLN1 (PPT1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CLN1</strong></td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Palmitoyl-Protein Thioesterase 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1p34.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/1204" target="_blank">1204</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132128" target="_blank">ENSG00000132128</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/256000" target="_blank">256000</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/O00624" target="_blank">O00624</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Infantile Neuronal Ceroid Lipofuscinosis (INCL)](/diseases/infantile-ceroid-lipofuscinosis)</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal Recessive</td>
</tr>
<tr>
<td class="label">Enzyme Class</td>
<td>Thioesterase</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

CLN1 (PPT1)

Overview

CLN1 encodes palmitoyl-protein thioesterase 1 (PPT1), a lysosomal enzyme that catalyzes the removal of palmitic acid (S-acylation) from modified proteins during lysosomal degradation[@vesa1995]. This enzyme is essential for the catabolism of lipid-modified (S-acylated) proteins within lysosomes. Pathogenic variants in CLN1 cause Infantile Neuronal Ceroid Lipofuscinosis (INCL), also known as Santavuori-Haltia disease, one of the most severe forms of Batten disease characterized by rapid neurodegeneration beginning in early infancy[@kohlschtter2019].

PPT1 deficiency represents one of the most rapidly progressive forms of neuronal ceroid lipofuscinosis, with most affected children developing severe neurological symptoms within the first year of life and succumbing to the disease by age 10-15 years. The discovery of CLN1 as the causative gene in 1995 was a landmark in understanding the molecular basis of these childhood dementia disorders[@vesa1995].

Gene Structure and Molecular Biology

Genomic Organization

The CLN1 gene is located on chromosome 1p34.2 and consists of 9 exons spanning approximately 16 kb of genomic DNA[@vesa1995]. The gene encodes a protein of 306 amino acids with a molecular weight of approximately 34 kDa. The protein is synthesized as a preproenzyme with an N-terminal signal peptide that directs it to the endoplasmic reticulum.

Protein Structure

PPT1 is a thioesterase enzyme belonging to the palmitoyl-protein thioesterase family[@hofmann2019]. The protein adopts a unique alpha-beta hydrolase fold with:

• A catalytic triad (Ser-Asp-His) typical of thioesterases
• A flexible N-terminal domain involved in substrate recognition
• A conserved oxyanion hole for stabilization of reaction intermediates
• Multiple glycosylation sites for proper folding and trafficking

Catalytic Mechanism

PPT1 catalyzes the hydrolysis of thioester bonds linking palmitic acid to cysteine residues in proteins[@sleat2005]:
R-CO-S-CH2-Protein + H2O → R-COOH + HS-CH2-Protein

This reaction requires:

• Active site serine (Ser115) as nucleophile
• Aspartate (Asp92) as catalytic base
• Histidine (Asp233) for proton transfer
• Water molecule for hydrolysis

Normal Biological Function

Lysosomal Protein Degradation

PPT1 plays a critical role in lysosomal protein catabolism by removing lipid modifications from proteins destined for degradation[@ballabio2016]. This process is essential because:

• Many neuronal proteins are S-acylated (palmitoylated) for membrane association
• Lysosomal degradation requires complete removal of all modifications
• Accumulation of improperly degraded proteins is toxic to neurons

Synaptic Function

PPT1 is highly expressed in neurons and regulates synaptic vesicle proteins[@lin2021]:

• Synaptic vesicle cycling: Removes palmitoyl groups from vesicle proteins
• Neurotransmitter release: Maintains proper synaptic vesicle function
• Neuronal plasticity: Regulates proteins involved in learning and memory
• Axonal transport: Modulates proteins involved in cargo trafficking

Autophagy

PPT1 deficiency impairs autophagic flux, leading to accumulation of autophagy substrates[@berg2020]. The enzyme is required for:

• Removal of palmitoylated autophagy proteins
• Fusion of autophagosomes with lysosomes
• Clearance of damaged organelles
• Cellular protein quality control

Disease Pathogenesis

CLN1 Disease (Infantile NCL)

Biallelic pathogenic variants in CLN1 cause Infantile Neuronal Ceroid Lipofuscinosis (INCL), also called Santavuori-Haltia disease[@kohlschtter2019]. This is one of the most severe forms of NCL.

Clinical Presentation

Children with INCL typically develop normally in the first months of life, followed by rapid neurological deterioration[@macs2019]:

• Early infancy (6-12 months): First signs appear
• Developmental delay
• Hypotonia (reduced muscle tone)
• Failure to achieve motor milestones
• Irritability, excessive crying
• Middle infancy (12-18 months): Rapid progression
• Loss of previously learned skills
• Seizures (often myoclonic)
• Visual impairment (due to retinal degeneration)
• Microcephaly (abnormally small head)
• Late infancy (18-36 months): Severe impairment
• Quadriplegia (loss of limb movement)
• Blindness
• Intractable seizures
• Severe cognitive impairment
• Childhood: Terminal phase
• Complete loss of motor function
• Refractory epilepsy
• Premature death (typically age 8-15 years)

Pathological Features

The accumulation of ceroid lipofuscin is the hallmark pathological finding[@mole2021]:

Lysosomal Storage Material

• Lipofuscin accumulation: Autofluorescent lipid-protein aggregates
• Membranous cytoplasmic inclusions: Characteristic ultrastructural finding
• Neuronal loss: Especially in cortex, cerebellum, and retina
• Gliosis: Reactive astrocytosis throughout the brain

Molecular Mechanisms

PPT1 deficiency leads to multiple downstream effects:

Mutation Spectrum

Types of Pathogenic Variants

Over 60 pathogenic variants have been identified in CLN1[@kousi2012]:

| Variant Type | Percentage | Common Examples |
|-------------|------------|------------------|
| Missense | 45% | p.Arg122Trp, p.Arg122Gln |
| Nonsense | 25% | p.Arg142, p.Trp178 |
| Splice site | 20% | c.451+1G>A |
| Small deletions | 8% | c.655delC |
| Large deletions | 2% | Exon deletions |

Genotype-Phenotype Correlations

• Severe alleles: Null alleles causing complete loss of function → earliest onset
• Milder alleles: Missense mutations with residual activity → later onset, slower progression
• Compound heterozygosity: Different severity alleles modify disease course

Common Founder Mutations

• p.Arg122Trp: Common in Finnish population (founder effect)
• p.Arg122Gln: Found in multiple populations
• c.451+1G>A: Recurrent splice mutation

Expression and Localization

Tissue Distribution

PPT1 is ubiquitously expressed with highest levels in[@sleat2005]:

| Tissue | Expression Level |
|--------|-----------------|
| Brain | Very high (neurons throughout CNS) |
| Retina | Very high (photoreceptors) |
| Liver | High |
| Kidney | High |
| Lung | Moderate |
| Heart | Moderate |
| Skeletal muscle | Low |

Subcellular Localization

PPT1 localizes to lysosomes via:

• N-terminal signal peptide (ER targeting)
• Mannose-6-phosphate modification (lysosomal targeting)
• Interaction with lysosomal hydrolases

Therapeutic Approaches

Gene Therapy

AAV-mediated gene therapy represents the most promising treatment approach[@sondhi2021]:

Clinical Trials

• Multiple Phase I/II trials completed
• AAV-PPT1 administered intravenously or intracerebroventricularly
• Demonstrated safety and preliminary efficacy
• Immune response management critical for success

Vector Development

• Self-complementary AAV vectors for robust expression
• Neuronal promoters for brain-specific expression
• Novel capsids for enhanced CNS transduction
• Systemic delivery strategies under development

Small Molecule Therapies

Enzyme Enhancement

• PPT1 activity enhancers under investigation
• Chemical chaperones to stabilize mutant proteins
• Proteostasis modulators to improve folding

Disease-Modifying Approaches

• Autophagy enhancers to clear storage material
• Anti-inflammatory agents to reduce neuroinflammation
• Antioxidants to address oxidative stress

Stem Cell Approaches

Transplantation of stem cells has been explored[@gieselmann2003]:

• Mesenchymal stem cells
• Neural stem cells
• Hematopoietic stem cells
• Gene-corrected autologous cells

Supportive Care

Current management focuses on symptomatic treatment:

• Seizure control: Multiple antiepileptic medications
• Visual impairment: Low vision aids, orientation training
• Motor dysfunction: Physical therapy, positioning
• Nutritional support: G-tube feeding as needed
• Communication: Alternative communication devices

Diagnosis

Clinical Diagnosis

Diagnosis involves multiple levels of evaluation[@kohlschtter2019]:

Clinical Assessment

• Detailed developmental history
• Neurological examination
• Ophthalmological evaluation
• Neuroimaging (MRI)

Laboratory Tests

• EEG (characteristic findings)
• Visual evoked potentials (abnormal)
• Nerve conduction studies

Biochemical Testing

• PPT1 enzyme activity: Deficient in patient leukocytes/fibroblasts
• Lysosomal enzyme panel: Rules out other LSDs
• Biomarkers: Neurofilament light chain (NfL) elevated

Molecular Genetic Testing

• Sequencing: Complete CLN1 coding and flanking regions
• Deletion/duplication analysis: Detects large rearrangements
• Panel testing: Multi-gene NCL panels available
• Whole exome sequencing: For atypical presentations

Prenatal Diagnosis

For families with known mutations:

• Chorionic villus sampling (10-12 weeks)
• Amniocentesis (15-18 weeks)
• Preimplantation genetic diagnosis (PGD)

Animal Models

Mouse Models

Mice with PPT1 deficiency recapitulate human disease[@smith2022]:

• Accumulation of lipofuscin in neurons
• Progressive neurodegeneration
• Motor deficits
• Reduced lifespan
• Visual impairment

Zebrafish Models

Zebrafish provide additional advantages:

• Rapid development and drug screening
• Transparent embryos for imaging
• Conservation of disease mechanisms

Epidemiology

CLN1 disease accounts for approximately 10-15% of all NCL cases[@mole2021]:

• Incidence: ~1:100,000 to 1:150,000 live births
• Equal male:female distribution
• Higher prevalence in populations with founder mutations
• Represents ~1,000-2,000 patients worldwide

Research Directions

Active Clinical Trials

Multiple trials are investigating new therapies[@johnson2024]:

• AAV gene therapy (Phase II/III)
• Small molecule therapies
• Stem cell transplantation
• Symptomatic management improvements

Emerging Technologies

• CRISPR gene editing for permanent correction
• Next-generation AAV vectors with enhanced CNS tropism
• Combination therapies targeting multiple pathways
• Biomarker development for treatment monitoring

Areas of Active Investigation

• Understanding genotype-phenotype correlations
• Developing outcome measures for clinical trials
• Identifying biomarkers of disease progression
• Optimizing delivery methods for CNS gene therapy

See Also

• [CLN2 (TPP1) — Late Infantile NCL](/genes/cln2)
• [CLN3](/genes/cln3) — Juvenile Batten Disease
• [CLN5](/genes/cln5) — Late Infantile NCL
• [CLN6](/genes/cln6) — Adult NCL
• [CLN7 (MFSD8) — Variant Late Infantile NCL](/genes/cln7)
• [CLN8](/genes/cln8) — Northern Epilepsy
• [Batten Disease](/diseases/batten-disease) — Overview of NCL disorders
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Infantile Neuronal Ceroid Lipofuscinosis](/diseases/infantile-ceroid-lipofuscinosis)

External Links

• [NCBI Gene: CLN1](https://www.ncbi.nlm.nih.gov/gene/1204)
• [UniProt: PPT1](https://www.uniprot.org/uniprot/O00624)
• [GeneCards: CLN1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLN1)
• [OMIM: 256000](https://omim.org/entry/256000)
• [Batten Disease Foundation](https://bdfa.org/)
• [NCL Resource: CLN1](https://www.nclresource.nl/)
• [ClinicalTrials.gov: CLN1](https://clinicaltrials.gov/)

Clinical Management

Seizure Management

Epilepsy is a central feature of CLN1 disease[@cialone2012]. Management requires multiple medications:

• First-line: Valproic acid, clonazepam
• Second-line: Levetiracetam, perampanel
• Myoclonic seizures: Clonazepam, valproic acid
• Status epilepticus: Benzodiazepines, phenytoin

• Generalized spike-wave discharges
• Myoclonic seizures correlates with EEG spikes
• Slowing of background activity with progression

Nutritional Support

Progressive disease leads to feeding difficulties:

• Dysphagia evaluation
• Weight monitoring
• Gastrostomy tube placement often required
• Prevention of aspiration

Respiratory Care

Respiratory complications are common:

• Recurrent infections
• Pneumonia risk
• Secretion management
• Non-invasive ventilation may be needed

Developmental Support

• Early intervention services
• Physical therapy for mobility
• Occupational therapy for daily activities
• Speech therapy for communication

Differential Diagnosis

Other NCL Subtypes

CLN1 disease must be distinguished from other forms[@mole2021]:

| Feature | CLN1 (INCL) | CLN2 (LINCL) | CLN3 (JNCL) | CLN5 |
|---------|-------------|--------------|-------------|------|
| Onset | 6-18 months | 2-4 years | 4-8 years | 2-7 years |
| Seizures | Early, severe | Common | Late | Variable |
| Visual loss | Early (1-2 years) | Early | Early | Variable |
| Motor decline | Severe | Severe | Mild | Moderate |
| Lifespan | 8-15 years | 10-20 years | 20-40 years | Variable |
| Gene | PPT1 | TPP1 | CLN3 | CLN5 |

Other Neurodegenerative Disorders

• Rett syndrome: Primarily affects females, different mutation
• Mitochondrial disorders: Different biochemical profile
• Leukodystrophies: White matter abnormalities on MRI
• Spinal muscular atrophy: Different genetic basis

Economic and Social Impact

Healthcare Burden

CLN1 disease imposes substantial costs:

• Diagnostic testing: $5,000-15,000
• Annual care: $100,000-500,000
• Gene therapy: $1-2 million (when available)
• Lost parental income

Family Impact

The rapid progression profoundly affects families:

• Psychological trauma
• Financial strain
• Caregiver burnout
• Sibling psychological effects

Support Resources

• Patient advocacy organizations
• Family support groups
• Respite care services
• Educational resources

Prevention

Genetic Counseling

Autosomal recessive inheritance means:

• 25% risk for each subsequent pregnancy
• Carrier testing available for family members
• PGD available for at-risk couples
• Prenatal testing for at-risk pregnancies

Population Screening

Newborn screening for NCLs is under development:

• Enzyme activity testing
• Genetic testing in pilot programs
• Early diagnosis enables early intervention

Future Directions

Gene Therapy Advances

Next-generation AAV vectors promise:

• Improved CNS transduction
• Reduced immune responses
• Longer duration of effect
• Lower effective doses

Combination Therapies

Future approaches may combine:

• Gene therapy with small molecules
• Anti-inflammatory agents with neuroprotective agents
• Symptomatic treatments with disease-modifying therapies

Biomarker Development

Research focuses on:

• Neurofilament light chain (NfL)
• Lysosomal storage markers
• Imaging biomarkers
• Functional outcome measures

International Collaboration

Global efforts are accelerating:

• International NCL registry
• Shared data resources
• Multi-center clinical trials
• Standardized care protocols

References